Cited 0 times in

Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients

Title
 Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients 
Authors
 Ji Yong Jang ; Sang Hak Lee ; Yangsoo Jang ; YeiLi Jung ; Jae Hyeon Juhn ; Tae Joon Cha ; June Namgung ; Kook Jin Chun ; Wook Bum Pyun ; Duk Hyun Kang ; Joo Hee Zo ; Ung Kim ; Deok Kyu Cho ; Choong Hwan Kwak ; Bum Soo Kim ; Kwang Soo Cha ; Hyoung Mo Yang ; Jang Ho Bae ; Bum Kee Hong ; Sang Ho Jo ; Tae Soo Kang ; Kwang Kon Koh ; Nae Hee Lee ; Youngkeun Ahn ; Woo Shik Kim ; Hong Seog Seo ; Byung Soo Kim 
Issue Date
2015
Journal Title
 Korean Circulation Journal (순환기) 
ISSN
 1738-5520 
Citation
 Korean Circulation Journal (순환기), Vol.45(3) : 225~233, 2015 
Abstract
BACKGROUND AND OBJECTIVES: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. SUBJECTS AND METHODS: Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. RESULTS: A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. CONCLUSION: Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/140442
DOI
10.4070/kcj.2015.45.3.225
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Internal Medicine
Yonsei Authors
사서에게 알리기
  feedback
Files in This Item:
T201502092.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse